Markston International’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Markston International’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-150	Closed	-$2K	–	186
2017 Q3	$2K	Hold	150	–	–	﹤0.01%	179
2017 Q2	$2K	Hold	150	–	–	﹤0.01%	182
2017 Q1	$2K	Hold	150	–	–	﹤0.01%	183
2016 Q4	$2K	Hold	150	–	–	﹤0.01%	194
2016 Q3	$3K	Hold	150	–	–	﹤0.01%	182
2016 Q2	$2K	Hold	150	–	–	﹤0.01%	180
2016 Q1	$2K	Hold	150	–	–	﹤0.01%	177
2015 Q4	$3K	Buy	+150	New	+$2.92K	﹤0.01%	186

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Markston International's HZNP Position: Q4 2017 in Review

Markston International sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2017, closing a stake of 150 shares — an estimated $2K sold.

Markston International first reported a position in HZNP in Q4 2015 and held it in 8 quarters. The position peaked at $3K in Q3 2016. 183 funds tracked by Wall St. Rank hold HZNP as of Q4 2017.

Markston International reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2017 after selling out during the quarter.
Markston International sold 150 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2017, an estimated $2K.
Markston International first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 8 quarters.
Markston International's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3K in Q3 2016.
183 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2017.

Based on Markston International's 13F filing for Q4 2017, filed 26 Jan 2018.